Centralized Management for Clinical Trial Communications and Workflows
Requests for radiological clinical trial evaluations frequently rely on fragmented methods such as emails, phone calls, and spreadsheets. This…
Categories: Therapy Response Assessment
Bridging the Gap Between RECIST and Survival: Why the FDA’s Analysis of the g Value is a Game-Changer
For decades, oncology trials have relied on RECIST 1.1 to evaluate drug efficacy. However, these categorical "snapshot" evaluations do not always…
ESOI-EORTC Workshop: Hands-On Training in Assessing Tumor Response to Treatment
The ESOI-EORTC workshop, hosted by the European Society of Oncological Imaging (ESOI) and the European Organization for Research and Treatment of…
University Hospital Cologne: Comparison of iRECIST and RECIST 1.1 for Evaluating Immunotherapy in Melanoma and Non-Small Cell Lung Cancer
A retrospective study conducted at University Hospital Cologne compared two criteria for assessing therapeutic response to immunotherapy: iRECIST and…
Use of Multiparametric MRI in Prostate Cancer Treatments: A Prospective Study
The prospective study conducted by LMU Klinikum München investigates the effectiveness of vascular-targeted photodynamic therapy (VTP) and…
Early Detection of Treatment Response in Lung Cancer Using Delta-Radiomics Features
The study conducted by Heidelberg University Hospital investigates the use of diffusion-weighted MRI (DWI) to predict early treatment outcomes in…
Heidelberg University Hospital: Delta-Radiomics Features from ADC Maps as Early Predictors of Treatment Success in Lung Cancer Therapy
In this prospective study conducted by Heidelberg University Hospital, researchers investigated whether changes in radiomic features from…
University Hospital Ulm: CT Radiomics and Machine Learning in Sarcopenia Evaluation for Esophageal and Gastric Cancer Patients
A recent study [1] conducted by researchers at University Hospital Ulm explored the role of sarcopenia in patients with esophageal or gastric cancer.…